Dueling Journal Commentaries Revisit FDA Approval of Abiomed's Impella

The pieces in JAMA Cardiology consider the merits of FDA's "515 Program Initiative" to classify preamendment devices and its application to a minimally invasive ventricular assist device.

Is FDA’s "515 Program Initiative

" for preamendment devices leading to approvals of high-risk devices based on flawed evidence? This question is addressed by two...

More from Regulation

More from Policy & Regulation